MX2019003241A - Moleculas de union que modulan una actividad biologica expresada por una celula. - Google Patents

Moleculas de union que modulan una actividad biologica expresada por una celula.

Info

Publication number
MX2019003241A
MX2019003241A MX2019003241A MX2019003241A MX2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A
Authority
MX
Mexico
Prior art keywords
cell
binding molecules
modulate
biological activity
activity expressed
Prior art date
Application number
MX2019003241A
Other languages
English (en)
Inventor
Throsby Mark
Anna Wilhelmina Geuijen Cecilia
Adriaan De Kruif Cornelis
Logtenberg Ton
Klooster Rinse
Johannes Tacken Paulus
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2019003241A publication Critical patent/MX2019003241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona medios y métodos para estimular la actividad de un miembro de la superfamilia de receptores del TNF en una célula. La invención proporciona, además, moléculas de unión tales como anticuerpos que comprenden al menos dos parátopos, en donde un primer parátopo puede unir una parte extracelular del miembro y un segundo parátopo puede unir una parte extracelular de una segunda proteína de membrana (diferente).
MX2019003241A 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula. MX2019003241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190499 2016-09-23
PCT/NL2017/050634 WO2018056821A1 (en) 2016-09-23 2017-09-22 Binding molecules that modulate a biological activity expressed by a cell

Publications (1)

Publication Number Publication Date
MX2019003241A true MX2019003241A (es) 2019-11-12

Family

ID=57132987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003241A MX2019003241A (es) 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula.

Country Status (19)

Country Link
US (2) US11685786B2 (es)
EP (2) EP3515951B1 (es)
JP (2) JP7305538B2 (es)
KR (1) KR20190065318A (es)
CN (2) CN109983033B (es)
AU (3) AU2017332452B2 (es)
BR (1) BR112019005895A2 (es)
CA (1) CA3038020A1 (es)
EA (1) EA201990578A1 (es)
ES (1) ES2981272T3 (es)
IL (2) IL311603A (es)
MA (1) MA46278A (es)
MX (1) MX2019003241A (es)
NZ (1) NZ751956A (es)
PH (1) PH12019550044A1 (es)
TW (1) TW201920653A (es)
UA (1) UA127449C2 (es)
WO (1) WO2018056821A1 (es)
ZA (1) ZA201902146B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
ES2858091T3 (es) 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA201990578A1 (ru) 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
EP3649156A1 (en) 2017-07-06 2020-05-13 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
JP2021519610A (ja) 2018-03-30 2021-08-12 メルス ナムローゼ フェンノートシャップ 多価抗体
SG11202009525VA (en) * 2018-03-30 2020-10-29 Eureka Therapeutics Inc Constructs targeting cd22 and uses thereof
EA202092420A1 (ru) 2018-04-09 2021-01-28 Ориджинселл Терапьютикс Ко., Лтд. Антитело против pd-l1 и его применение
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
JP7360440B2 (ja) 2018-07-12 2023-10-12 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
EP3636320A1 (en) * 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
MX2021005085A (es) * 2018-11-06 2021-11-04 Genmab As Formulacion de anticuerpo.
AU2020276500A1 (en) * 2019-05-10 2021-12-16 Lyvgen Biopharma Holdings Limited Humanized anti-CD137 antibodies and uses thereof
CN118791614A (zh) * 2019-06-26 2024-10-18 圆祥生技股份有限公司 T细胞活化抗体
EP4041772A4 (en) * 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co., Ltd. 4-1BB-BINDING ANTIBODIES AND USES THEREOF
JP2023513896A (ja) * 2020-02-04 2023-04-04 ジェンマブ エー／エス 療法において使用するための抗体
EP4106813A4 (en) * 2020-02-21 2024-03-27 MacroGenics, Inc. CD137-BINDING MOLECULES AND USES THEREOF
US20230172189A1 (en) * 2020-04-28 2023-06-08 Ohio University Methods for Extending the Shelf-life of Stored Donor Blood and/or Red Blood Cells and Treated Red Blood Cell Compositions Produced Thereby
AR122132A1 (es) 2020-05-21 2022-08-17 Merus Nv Métodos y medios para producción de moléculas tipo ig
IL300225A (en) * 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
EP4262853A1 (en) 2020-12-16 2023-10-25 Merus N.V. Multispecific antibodies for the treatment of cancer
US20240309115A1 (en) 2021-03-31 2024-09-19 Merus N.V. Novel multispecific antibodies
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023225098A1 (en) * 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
BR0108001A (pt) * 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2005327973A1 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
PT2147594E (pt) 2008-06-27 2014-02-17 Merus B V Mamíferos não humanos que produzem anticorpos
CN102245640B (zh) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
MX2011009729A (es) 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
KR20130087517A (ko) 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물
NZ714128A (en) 2010-09-09 2017-10-27 Pfizer 4-1bb binding molecules
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2014343636A1 (en) * 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
WO2015095423A2 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
JP6629187B2 (ja) 2014-04-07 2020-01-15 中外製薬株式会社 免疫活性化抗原結合分子
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
EP3623386B1 (en) 2015-01-08 2022-04-13 BioNTech SE Agonistic tnf receptor binding agents
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
US20180044429A1 (en) * 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
JP6955445B2 (ja) * 2015-04-07 2021-10-27 ジェネンテック， インコーポレイテッド アゴニスト性の活性を有する抗原結合複合体及びその使用方法
US11008396B2 (en) * 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108271377B (zh) 2015-10-07 2021-11-19 豪夫迈·罗氏有限公司 具有针对共刺激性tnf受体的四价的双特异性抗体
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
US20200048345A1 (en) * 2015-12-28 2020-02-13 Innate Pharma Multispecific antigen binding proteins
AU2017207318B2 (en) * 2016-01-11 2023-12-07 Inhibrx Biosciences, Inc. Multivalent and multispecific OX40-binding fusion proteins
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
EP3445788B1 (en) * 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EA201990578A1 (ru) 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
IL265541A (en) 2019-05-30
BR112019005895A2 (pt) 2019-06-11
EP4342912A3 (en) 2024-05-22
US11685786B2 (en) 2023-06-27
JP2019537429A (ja) 2019-12-26
US20200017595A1 (en) 2020-01-16
CN117510643A (zh) 2024-02-06
US20240209105A1 (en) 2024-06-27
EA201990578A1 (ru) 2019-10-31
JP7305538B2 (ja) 2023-07-10
IL265541B2 (en) 2024-08-01
TW201920653A (zh) 2019-06-01
EP3515951B1 (en) 2024-02-28
AU2017332452B2 (en) 2021-01-07
IL311603A (en) 2024-05-01
AU2024220074A1 (en) 2024-10-17
WO2018056821A8 (en) 2019-05-02
IL265541B1 (en) 2024-04-01
UA127449C2 (uk) 2023-08-30
CA3038020A1 (en) 2018-03-29
AU2017332452A1 (en) 2019-04-11
AU2021202085A1 (en) 2021-04-29
AU2021202085B2 (en) 2024-07-11
MA46278A (fr) 2019-07-31
CN109983033B (zh) 2023-10-31
EP3515951A1 (en) 2019-07-31
EP4342912A2 (en) 2024-03-27
ZA201902146B (en) 2024-08-28
ES2981272T3 (es) 2024-10-08
CN109983033A (zh) 2019-07-05
NZ751956A (en) 2022-01-28
PH12019550044A1 (en) 2019-11-11
JP2023116811A (ja) 2023-08-22
KR20190065318A (ko) 2019-06-11
WO2018056821A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
ZA201902146B (en) Binding molecules that modulate a biological activity expressed by a cell
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MX2024007576A (es) Celulas que expresan receptores de activacion quimericos y receptores estimulantes quimericos y usos de estos.
MX2024007711A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
MX2021003436A (es) Anticuerpos humanos para pd-1.
WO2016179518A8 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
NZ767674A (en) Antigen binding molecules comprising a tnf family ligand trimer
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
MX2017009793A (es) Agentes de union de la superfamilia del receptor de factor de necrosis tumoral y usos de los mismos.
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EP4249066A3 (en) Antibodies to tigit
WO2013184912A3 (en) Binding agents that modulate the hippo pathway and uses thereof
WO2014031646A3 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2019105468A8 (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
EA201892440A1 (ru) Антитела к tl1a и их применения
EP4414034A3 (en) Antibodies specific for cd3 and uses thereof
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1